Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrew J. Armstrong, Daniel P. Petrylak, Neal D. Shore, Russell Zelig Szmulewitz, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Alexis Serikoff, Ruslan Croitoru, Matt Rosales, Matko Kalac, Yiyun Tang, Arnulf Stenzl, Arun Azad
Institutions: Duke Cancer Institute, Yale University, University of Chicago, University of Kansas Medical Center, Université de Lille, Hospital Clínic de Barcelona, P.A. Hertzen Moscow Oncology Research Institute, Kanazawa Medical University, Complexo Hospitalario Universitario A Coruña, Astellas Pharma (United States), Pfizer (United States), University of Tübingen, Peter MacCallum Cancer Centre
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W7162513657
Cites:
Cited by:
Related to: